abrdn Healthcare Investors (NYSE:HQH) Sets New 12-Month High – What’s Next?

abrdn Healthcare Investors (NYSE:HQH)’s stock price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $21.91 and last traded at $21.84, with a volume of 75456 shares trading hands. The stock had previously closed at $21.63.

abrdn Healthcare Investors Stock Performance

The firm has a 50-day moving average price of $19.77 and a 200-day moving average price of $19.22.

abrdn Healthcare Investors Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Thursday, May 21st will be given a dividend of $0.61 per share. The ex-dividend date is Thursday, May 21st. This represents a $2.44 annualized dividend and a yield of 11.1%.

Institutional Trading of abrdn Healthcare Investors

Several hedge funds have recently added to or reduced their stakes in the stock. Bollard Group LLC purchased a new position in abrdn Healthcare Investors in the first quarter valued at about $25,000. Flagship Harbor Advisors LLC purchased a new stake in shares of abrdn Healthcare Investors during the 4th quarter worth approximately $48,000. Geneos Wealth Management Inc. raised its holdings in shares of abrdn Healthcare Investors by 9,232.3% in the 2nd quarter. Geneos Wealth Management Inc. now owns 2,893 shares of the financial services provider’s stock worth $45,000 after purchasing an additional 2,862 shares during the period. Advisory Services Network LLC bought a new stake in shares of abrdn Healthcare Investors in the 3rd quarter worth approximately $97,000. Finally, Global Retirement Partners LLC purchased a new position in abrdn Healthcare Investors in the fourth quarter valued at approximately $106,000. Institutional investors own 32.60% of the company’s stock.

abrdn Healthcare Investors Company Profile

abrdn Healthcare Investors (NYSE:HQH) is a closed-end management investment company that seeks long-term capital appreciation and current income by investing primarily in equity securities of companies operating in the healthcare sector. The fund’s portfolio generally comprises a diversified mix of domestic and international healthcare issuers, spanning pharmaceuticals, biotechnology, medical devices, healthcare services, and related industries.

The fund employs a fundamental, research-driven approach to select investments, focusing on companies with strong balance sheets, innovative product pipelines and the potential for sustainable revenue growth.